Skin Spectrum Weekly

Share this post

Topical biofilm-disruptor shows promise for acne Tx

skin.substack.com

Topical biofilm-disruptor shows promise for acne Tx

Today's report also covers interactions of sarecycline and C. acnes, teledermatology follow-ups, RF microneedling, and more (1,400 words, 7 minutes, 40 seconds)

Jeremy Visser
May 5, 2023
10
Share
The Focus on Acne e-newsletter is supported by an unrestricted grant from Sun Pharma Canada

Good morning and welcome to the first issue of Focus on Acne presented by Skin Spectrum Weekly. This series provides up-to-date information on developing therapies and trends in acne treatment. We appreciate your feedback and suggestions and invite you to be in touch. Please write to us at health@chronicle.org

Topical biofilm-disruptor shows promise for acne Tx

A six-month randomized, double-blind, controlled study has found that a biofilm-disrupting acne cream provides equivalent efficacy to 2.5% benzoyl peroxide (BPO) gel with fewer adverse effects.

The findings were published in The Journal of Clinical and Aesthetic Dermatology (April 2023; 16(4):43-52).

The study involved female subjects with mild-to-moderate acne treated daily with one of two formulations of a biofilm-disrupting acne cream containing salicylic acid (known as 1x and 2x), a formulation of the cream without salicylic acid, 2.5% BPO gel, or a placebo. Subjects applied the assigned product to their face twice daily and were evaluated for clinical acne and quality of life outcomes at baseline and after six, 12, 18, and 24 weeks of treatment.

After 24 weeks of use, subjects treated with biofilm-disrupting acne cream 2x had a significantly greater improvement in the Investigator Global Assessment (IGA), compared to those treated with 2.5% BPO gel. Additionally, biofilm-disrupting acne cream 2x, biofilm-disrupting acne cream 1x, biofilm-disrupting acne cream without salicylic acid, and placebo control were associated with less erythema and dryness, compared to 2.5% BPO gel. However, the study’s assessments had the potential for subjective differences due to variability between evaluators.

Overall, the biofilm-disrupting acne cream 2x and biofilm-disrupting acne cream 1x provided equivalent efficacy to 2.5% BPO gel with fewer adverse effects, while the biofilm-disrupting acne cream without salicylic acid and placebo control were associated with mild improvements to acne symptoms over the course of the 24-week study.

Link to article

Unique interactions of sarecycline and C. acnes identified

A new study has identified how the third-generation tetracycline antibiotic sarecycline has a strong specificity for C. acnes while also seeming to have a low risk of encouraging antibiotic resistance.

Published in Nucleic Acids Research (April 11, 2023; 51(6):2915-2930), the study describes how researchers visualized the C. acnes ribosome and how sarecycline interacts with it.

“This is a huge step in the right direction towards pathogen-specific antibiotic development,” said the study’s principal investigator Christopher Bunick, MD, PhD, in a press release. “If we can understand sarecycline’s low propensity for antibiotic resistance in C. acnes, that allows for the future development of even more targeted and safer antibiotics or other medicines with minimal resistance risk.”

Dr. Bunick is an associate professor of dermatology at the Yale School of Medicine in New Haven, Conn.

The investigation revealed that, unlike other antibiotics, sarecycline is bound to not one, but two active sites on the ribosome. Earlier studies of sarecycline in the model ribosome of the bacteria Thermus thermophilus found only one binding site.

The authors write that the second binding site is similar to one that interacts with the macrolides class of antibiotics.

According to the release, these findings are important for two reasons. First, this is the first group to visualize the structure of the C. acnes ribosome itself and make several observations. C. acnes ribosomes have proteins with zinc-free and zinc-bound isoforms. Some dermatology research suggests that zinc supplementation might help treat acne vulgaris and support antibiotic treatments. This work further supports that zinc supplementation may help treat acne.

Second, the model explains why sarecycline use is less likely to lead to antibiotic-resistant mutations.

“The probability of having a mutation at one ribosomal site is high, but the probability of having mutations at two sites at the same time is much lower,” said the paper’s lead author Ivan Lomakin, PhD, an associate research scientist in dermatology at Yale.

Link to article

This is the first study to visualize the structure of the C. acnes ribosome itself and make several observations.

Teledermatology for acne follow-up reduces patient burden

A randomized clinical trial published in Acta Informatica Medica (March 2023; 31(1):31-36) has found that teledermatology can provide effective follow-up for patients with mild-to-moderate acne.

The study, which compared teledermatology versus face-to-face consultation in 24 patients with acne vulgaris, found that while the cumulative time spent by the physician was higher in the teledermatology group, the cumulative time spent by the patient was significantly lower.

Both groups showed optimal reduction of acne severity, without significant differences between them. Patient satisfaction did not change significantly over time and between groups and was generally high. Adverse events were reported by one patient in the teledermatology group and four patients in the consultation group.

The study concludes that teledermatology could be an optimal approach for following up with patients with acne because it can reduce the burden on patients and medical staff. However, the implementation of more user-friendly platforms is necessary to achieve the best possible results in the treatment and follow-up of acne patients.

Link to article

The authors concluded that teledermatology could be an optimal approach for following up with acne patients, as it can reduce the burden on patients and staff.

RF microneedling/isotretinoin combination results in faster, longer-lasting acne improvement

New findings suggest that combining isotretinoin acne treatment with radiofrequency (RF) microneedling is safe and effective, has a quicker response, causes less scarring, and reduces recurrence compared to isotretinoin alone.

The cross-sectional study, published in Postępy Dermatologii i Alergologii (Feb. 2023; 40(1):111-114) compared the effectiveness and safety of an automated RF microneedling device and oral isotretinoin to isotretinoin alone for treating active acne. The study included 40 moderate acne patients who were divided into two groups: Group A, which included 20 patients treated with an automated RF microneedling device and isotretinoin 0.5-1 mg/kg, and Group B, which included 20 patients who were given a single dose of 0.5-1 mg/kg isotretinoin.

Researchers found that after 12 weeks, Group A showed better global acne assessment scale (GAAS) outcomes than Group B, and after six months, Group A showed better results than Group B. The GAAS did not change after four to eight weeks of treatment, and there were no differences in age or weight between the two groups.

Link to article

Acne treatment with isotretinion and radiofrequency microneedling has a quick response, causes less scarring, reduces recuurence compared to isotretinoin alone, and is safe and effective, according to the study.

Subscribe to The Chronicle of Skin & Allergy

Established in 1995, The Chronicle of Skin & Allergy is a scientific newspaper providing news and information on practical therapeutics and clinical progress in dermatologic medicine.

Click the cover (above) to access a recent issue

To apply for a complimentary* subscription, please email health@chronicle.org with your contact information or click the link below.

Subscribe

If you find the contents of this newsletter interesting, please check out the Yadav on Acne podcast. It’s available at Apple iTunes, Stitcher, Spotify, or wherever you get your podcasts.

You are receiving this newsletter because you subscribe to The Chronicle of Skin & Allergy or another Chronicle journal, have attended a Skin Spectrum Summit live event or webinar, or have previously requested a subscription to one of our newsletters. If you no longer wish to subscribe to this newsletter, please email the subject line “Unsubscribe Skin Spectrum Weekly” to health@chronicle.org.
Skin Spectrum Weekly is published by Chronicle Companies, 701 Ellicott Street, Buffalo, NY 14203. Canada: 555 Burnhamthorpe Road, Suite 306, Toronto, Ont. M9C 2Y3
Mitchell Shannon, Publisher; R. Allan Ryan, Editorial Director; John Evans, Managing Editor; Kylie Rebernik, Jeremy Visser, Editors; Cristela Tello Ruiz, Client Services
Content is copyright (c) 2023, Chronicle LifeSci America Corp, except as indicated. Interested in contributing to this newsletter or learning more about Chronicle’s services? Please write to us at info@skinspectrum.us
10
Share
Comments
Top
New
Community

No posts

Ready for more?

© 2023 Skin Spectrum Weekly
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing